Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest

被引:80
作者
Kriegs, Malte [1 ]
Gurtner, Kristin [5 ]
Can, Yildiz [1 ]
Brammer, Ingo [1 ]
Rieckmann, Thorsten [1 ]
Oertel, Reinhai. D. [6 ,7 ]
Wysocki, Marek [5 ]
Dorniok, Franziska [5 ]
Gal, Andreas [2 ]
Grob, Tobias J. [3 ]
Laban, Simon [4 ]
Kasten-Pisula, Ulla [1 ]
Petersen, Cordula [1 ]
Baumann, Michael [5 ,8 ,9 ,10 ]
Krause, Mechthild [5 ,8 ,9 ,10 ]
Dikomey, Ekkehard [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Lab Radiobiol & Expt Radiooncol, D-020246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Human Genet, D-020246 Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, D-020246 Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Dept Otorhinolaryngol & Head & Neck Surg, D-020246 Hamburg, Germany
[5] Tech Univ Dresden, Fac Med, Natl Ctr Radiat Res Oncol, Dept Radiat Oncol & OncoRay, Dresden, Germany
[6] Tech Univ Dresden, Fac Med, Inst Clin Pharmacol, Dresden, Germany
[7] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany
[8] German Canc Consortium DKTK Dresden, Dresden, Germany
[9] German Canc Res Ctr DKEZ Heidelberg, Heidelberg, Germany
[10] Hemholtz Zentrum Dresden Rossendorf, Dresden, Germany
关键词
EGFR inhibition; Radiosensitization; NSCLC; Cell cycle; G1; arrest; p53; GROWTH-FACTOR-RECEPTOR; LUNG-CANCER CELLS; MUTATIONAL LANDSCAPE; RADIATION-THERAPY; G(1) ARREST; GEFITINIB; HEAD; RADIOTHERAPY; MECHANISMS; CETUXIMAB;
D O I
10.1016/j.radonc.2015.02.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: How EGF receptor (EGFR) inhibition induces cellular radiosensitization and with that increase in tumor control is still a matter of discussion. Since EGFR predominantly regulates cell cycle and proliferation, we studied whether a G1-arrest caused by EGFR inhibition may contribute to these effects. Materials and methods: We analyzed human non-small cell lung cancer (NSCLC) cell lines either wild type (wt) or mutated in p53 (A549, H460, vs. H1299, H3122) and HCT116 cells (p21 wt and negative). EGFR was inhibited by BIBX1382BS, erlotinib or cetuximab; p21 was knocked down by siRNA. Functional endpoints analyzed were cell signaling, proliferation, G1-arrest, cell survival as well as tumor control using an A549 tumor model. Results: When combined with IR, EGFR inhibition enhances the radiation-induced permanent G1 arrest, though solely in cells with intact p53/p21 signaling. This increase in G1-arrest was always associated with enhanced cellular radiosensitivity. Strikingly, this effect was abrogated when cells were re-stimulated, suggesting the initiation of dormancy. In line with this, only a small non-significant increase in tumor control was observed for A549 tumors treated with fractionated RT and EGFR inhibition. Conclusion: For NSCLC cells increase in radiosensitivity by EGFR inhibition results from enhanced G1 arrest. However, this effect does not lead to improved tumor control because cells can be released from this arrest by re-stimulation. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:120 / 127
页数:8
相关论文
共 41 条
[1]
Amann J, 2005, CANCER RES, V65, P226
[2]
Ang KK, 2002, CANCER RES, V62, P7350
[3]
[Anonymous], J CLIN ONCOL
[4]
Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results [J].
Baumann, M ;
Krause, M .
RADIOTHERAPY AND ONCOLOGY, 2004, 72 (03) :257-266
[5]
Short-Course Treatment With Gefitinib Enhances Curative Potential of Radiation Therapy in a Mouse Model of Human Non-Small Cell Lung Cancer [J].
Bokobza, Sivan M. ;
Jiang, Yanyan ;
Weber, Anika M. ;
Devery, Aoife M. ;
Ryan, Anderson J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04) :947-954
[6]
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[7]
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].
Bonner, James A. ;
Harari, Paul M. ;
Giralt, Jordi ;
Cohen, Roger B. ;
Jones, Christopher U. ;
Sur, Ranjan K. ;
Raben, David ;
Baselga, Jose ;
Spencer, Sharon A. ;
Zhu, Junming ;
Youssoufian, Hagop ;
Rowinsky, Eric K. ;
Ang, K. Kian .
LANCET ONCOLOGY, 2010, 11 (01) :21-28
[8]
For x-irradiated normal human fibroblasts, only half of cell inactivation results from chromosomal damage [J].
Borgmann, K ;
Dede, M ;
Wrona, A ;
Brammer, I ;
Overgaard, J ;
Dikomey, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (02) :445-452
[9]
A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and Maintenance Gefitinib for Patients with Stage III Non-small Cell Lung Cancer [J].
Center, Brian ;
Petty, William Jeffrey ;
Ayala, Diandra ;
Hinson, William H. ;
Lovato, James ;
Capellari, James ;
Oaks, Timothy ;
Miller, Antonius A. ;
Blackstock, Arthur William .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) :69-74
[10]
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience [J].
Chang, Chih-Chia ;
Chi, Kwan-Hwa ;
Kao, Shang-Jyh ;
Hsu, Pei-Sung ;
Tsang, Yuk-Wah ;
Chang, Heng-Jui ;
Yeh, Yu-Wung ;
Hsieh, Yei-San ;
Jiang, Jiunn-Song .
LUNG CANCER, 2011, 73 (02) :189-194